Pax5 controls the identity and development of B cells by repressing lineage-inappropriate genes and activating B-cell-specific genes. Here, we used genome-wide approaches to identify Pax5 target genes in pro-B and mature B cells. In these cell types, Pax5 bound to 40% of the cisregulatory elements defined by mapping DNase I hypersensitive (DHS) sites, transcription start sites and histone modifications. Although Pax5 bound to 8000 target genes, it regulated only 4% of them in pro-B and mature B cells by inducing enhancers at activated genes and eliminating DHS sites at repressed genes. Pax5-regulated genes in pro-B cells account for 23% of all expression changes occurring between common lymphoid progenitors and committed pro-B cells, which identifies Pax5 as an important regulator of this developmental transition. Regulated Pax5 target genes minimally overlap in pro-B and mature B cells, which reflects massive expression changes between these cell types. Hence, Pax5 controls B-cell identity and function by regulating distinct target genes in early and late B lymphopoiesis. The EMBO Journal (2012) (Nutt and Kee, 2007) . The helix-loop-helix protein E2A and the early B-cell factor EBF1 specify the B-cell lineage by activating the expression of B-lymphoid genes in pre-pro-B cells Treiber et al, 2010) . Pax5 subsequently controls B-cell commitment at the transition to the pro-B cell stage by restricting the developmental potential of lymphoid progenitors to the B-cell lineage, as shown by the fact that Pax5-deficient pro-B cells are still able to differentiate into most hematopoietic cell types in vitro and in vivo (Nutt et al, 1999; Medvedovic et al, 2011) . At the molecular level, Pax5 fulfills a dual role by repressing B-lineage-inappropriate genes to suppress alternative lineage options and by simultaneously activating B-cell-specific genes to promote B-cell development (Nutt et al, 1999; Medvedovic et al, 2011) . Gene expression analyses of wild-type and Pax5-deficient pro-B cells identified 110 Pax5-repressed and 170 Pax5-activated genes, which code for key regulatory and structural proteins involved in transcriptional control, receptor signalling, adhesion, migration and immune function (Delogu et al, 2006; Schebesta et al, 2007; Pridans et al, 2008) . Pax5 regulates these gene expression changes by inducing active chromatin at activated target genes and eliminating active chromatin at repressed genes in pro-B cells . Notably, Pax5 induces these chromatin and transcription changes by recruiting chromatin-remodelling, histone-modifying and basal transcription factor complexes to its target genes, which identifies Pax5 as an epigenetic regulator of B-cell commitment .
Introduction
Hematopoietic stem cells (HSCs) in the bone marrow give rise to all mature B-cell types in peripheral lymphoid organs by first differentiating to lymphoid-primed multipotent progenitors (LMPPs) and common lymphoid progenitors (CLPs), which consist of Ly6D À all-lymphoid progenitors (ALPs) and Ly6D þ B-cell-biased lymphoid progenitors (BLPs; Inlay et al, 2009 ). ALPs retain the full lymphoid potential as they are able to develop into B, T, NK and DC cells (Inlay et al, 2009) . In contrast, BLPs initiate the B-cell gene expression programme and preferentially differentiate via the pre-pro-B cell stage to pro-B cells, which undergo B-lineage commitment and subsequent development to mature B cells (Hardy et al, 2007; Inlay et al, 2009 ). B-cell commitment depends on the sequential activity of the instructive transcription factors E2A, EBF1 and Pax5 during the development of CLPs to pro-B cells (Nutt and Kee, 2007) . The helix-loop-helix protein E2A and the early B-cell factor EBF1 specify the B-cell lineage by activating the expression of B-lymphoid genes in pre-pro-B cells Treiber et al, 2010) . Pax5 subsequently controls B-cell commitment at the transition to the pro-B cell stage by restricting the developmental potential of lymphoid progenitors to the B-cell lineage, as shown by the fact that Pax5-deficient pro-B cells are still able to differentiate into most hematopoietic cell types in vitro and in vivo (Nutt et al, 1999; Medvedovic et al, 2011) . At the molecular level, Pax5 fulfills a dual role by repressing B-lineage-inappropriate genes to suppress alternative lineage options and by simultaneously activating B-cell-specific genes to promote B-cell development (Nutt et al, 1999; Medvedovic et al, 2011) . Gene expression analyses of wild-type and Pax5-deficient pro-B cells identified 110 Pax5-repressed and 170 Pax5-activated genes, which code for key regulatory and structural proteins involved in transcriptional control, receptor signalling, adhesion, migration and immune function (Delogu et al, 2006; Schebesta et al, 2007; Pridans et al, 2008) . Pax5 regulates these gene expression changes by inducing active chromatin at activated target genes and eliminating active chromatin at repressed genes in pro-B cells . Notably, Pax5 induces these chromatin and transcription changes by recruiting chromatin-remodelling, histone-modifying and basal transcription factor complexes to its target genes, which identifies Pax5 as an epigenetic regulator of B-cell commitment .
Pax5 is expressed throughout B-cell development from pro-B cells in the bone marrow to mature B cells in peripheral lymphoid organs (Fuxa and Busslinger, 2007) , where it plays an important role in the generation and function of distinct mature B-cell types (Horcher et al, 2001; Medvedovic et al, 2011) . Pax5 is essential for maintaining the B-cell gene expression programme in late B lymphopoiesis, as conditional inactivation of Pax5 leads to the down-regulation of B-cellspecific genes and reactivation of lineage-inappropriate genes in mature B cells (Horcher et al, 2001; Delogu et al, 2006; Schebesta et al, 2007) . Importantly, the conditional loss of Pax5 results in the conversion of mature B cells into functional T cells by dedifferentiation to uncommitted progenitors in the bone marrow (Cobaleda et al, 2007) . Loss of the B-cell phenotype upon conditional Pax5 inactivation highlights an important role of Pax5 in the maintenance of B-cell identity throughout B lymphopoiesis (Mikkola et al, 2002; Cobaleda et al, 2007) . The question therefore arises whether Pax5 regulates a similar or different set of target genes to control the identity and function of B lymphocytes in early and late B-cell development. Our current knowledge about the molecular function of Pax5 in B lymphopoiesis is, however, too fragmentary to answer this question, as very few Pax5-regulated genes have so far been identified in mature B cells (Delogu et al, 2006; Schebesta et al, 2007) and only 1.6% of the mouse genome has recently been screened by chromatin immunoprecipitation (ChIP)-chip analysis for Pax5 target genes (defined as Pax5-bound genes) in pro-B cells .
Here, we have used genome-wide sequencing approaches to define the cis-regulatory landscape and to identify regulated Pax5 target genes in committed pro-B and mature B cells. Whereas Pax5 bound to a large part (40%) of the cisregulatory genome, it regulated only a small subset of its target genes in early and late B-cell development. However, the regulated Pax5 target genes in pro-B cells accounted for a relatively large part (23%) of the gene expression changes occurring during B-cell commitment. Notably, only a minimal overlap was observed between regulated Pax5 target genes in pro-B and mature B cells, indicating that Pax5 controls the identity and function of B cells by regulating distinct target genes in early and late B-cell development.
Results

Genome-wide identification of regulatory elements in pro-B and mature B cells
To define the cis-regulatory landscape, we characterized the genome-wide pattern of protein-DNA interactions by identifying DNase I hypersensitive (DHS) sites in early and late B-cell development. To this end, short-term cultured Rag2
À / À pro-B cells were treated with DNase I to excise DHS sequences followed by deep sequencing of the released DNase I 'doublehit' fragments (Sabo et al, 2006; Hesselberth et al, 2009) . This large-scale analysis resulted in the identification of 36 844 DHS sites, which were called with a stringent P-value of o10 À 10 as shown for the Cd79b gene ( Figure 1A ). To identify active promoters (AP) among these DHS sites, we performed cap analysis of gene expression (CAGE) coupled with deep sequencing. CAGE is a cap-trapping-based method that allows the systematic 5 0 end profiling of capped mRNAs to generate comprehensive maps of transcription start sites (TSSs) at single-nucleotide resolution (Shiraki et al, 2003; Carninci et al, 2006) . To identify active TSSs defining active promoters, we applied a cutoff of 2.6 RPM (reads per CAGE tag cluster per million mapped sequence tags), which distinguishes transcriptionally active (42.6 RPM) from inactive (o2.6 RPM) genes (Supplementary Figure S1A Figure 1 Genome-wide identification of cis-regulatory elements in pro-B and mature B cells. (A) Identification of active promoters and distal elements in pro-B cells. Short-term cultured Rag2 À / À pro-B cells (CD19 þ B220 þ ) were used for CAGE and DHS site analysis combined with deep sequencing as described in Supplementary Materials and Methods and Supplementary Table S1 . Active promoters were defined by the cooccurrence of DHS sites with active TSSs, which were determined by the presence of CAGE sequence tags above 2.6 RPM (reads per CAGE tag cluster per million mapped sequence tags; Supplementary Figure S1A and B), as shown for the Cd79b gene (left). Distal elements (DE) were defined by the presence of DHS site in the absence of transcription initiation (CAGE sequence tags below 2.6 RPM). A pie chart (right) indicates the total number of distal elements, active annotated promoters (AP, present in RefSeq) and non-annotated active promoters (NAP, absent in RefSeq), which were defined by the presence of a DHS site and active TSS. Due to the stringent P-value (o10 À 10 ) used, DHS sites were not called at 896 annotated promoters (AP*, present in RefSeq) that qualified, however, as active promoters due to the presence of active TSSs. The genomic coordinates of the identified promoters and distal elements are provided in Supplementary [CAGE] ). (C) Overlap of regulatory elements in pro-B and mature B cells. Black bars indicate common DHS sites, active promoters and distal elements between pro-B and mature B cells (left), and grey bars denote unique regulatory elements in the respective cell type (left). Average sequence tag density profiles aligned at the central position of the DHS sites are shown for common and unique distal elements in the two cell types (right). Similar data were obtained by analysing a second DHS site mapping experiment of pro-B and mature B cells, whereas the CAGE analysis was performed only once for each cell type (Supplementary Table S1 ).
as exemplified for the Cd79b gene ( Figure 1A ). Among these active promoters, 1351 (13.1%) correspond to newly identified active promoters (NAP) that have not been annotated in the RefSeq database as demonstrated by Arntl, Spib and Bach2 (Supplementary Figure S1C) . Moreover, 896 RefSeq-annotated promoters (AP*) contained active TSSs with CAGE tags above 2.6 RPM, although DHS sites were not called at the stringent Pvalue of o10 À 10 ( Figure 1A) . We refer to all other DHS sites (26 554) that do not overlap with active TSSs as distal elements (DE), which account for 72% of all accessible cis-regulatory elements in pro-B cells ( Figure 1A ). We next isolated quiescent mature B cells from lymph nodes (Supplementary Figure S1D) for CAGE and DHS site mapping, which identified a similar number and relative distribution of active promoters (9730; 31%) and distal elements (21 357; 69%) in mature B cells ( Figure 1B ; Supplementary Figure S1C ) compared with pro-B cells ( Figure 1A) . A large fraction (63-68%) of the identified DHS sites were present in both pro-B and mature B cells ( Figure 1C ). Almost all active promoters (82-86%) were common to both cell types, whereas only half of the distal elements (45-56%) were shared between pro-B and mature B cells ( Figure 1C ) consistent with previous findings that enhancers (among the distal elements) are highly cell type specific in contrast to the largely invariant promoter usage observed across different cell types (Heintzman et al, 2009) . As shown by density plot analysis, the common distal elements exhibited a similar degree of DNase I hypersensitivity in both cell types, whereas the unique distal elements were characterized by a higher tag density in pro-B or mature B cells, respectively ( Figure 1C, right) . By assigning the distal elements to their closest gene, we identified six distinct gene classes with different assortments of common and unique distal elements (Supplementary Figure S2) . In summary, the genome-wide analysis of DHS sites and TSSs has defined the cis-regulatory landscape by identifying distal elements and active promoters in pro-B and mature B cells.
Identification of active enhancers and inactive distal elements in pro-B and mature B cells
As active promoters and enhancers are characterized by specific chromatin signatures (Zhou et al, 2011) , we further characterized the identified active promoters and distal elements by genome-wide profiling of active (H3K4me1, H3K4me2, H3K4me3, H3K9ac) and repressive (H3K27me3) histone modifications using ChIP coupled with deep sequencing (ChIP-seq). By calling these histone modifications with a stringent P-value of o10 À 10 , we could demonstrate that almost all active promoters (95%) in Rag2 À / À pro-B cells carried high levels of the three active histone marks H3K4me2, H3K4me3 and H3K9ac adjacent to their DHS site, as shown by global analysis (Figure 2A ), a specific example ( Figure 2B ) and quantitative profiles of sequence tag densities ( Figure 2C ). These data confirmed that the co-occurrence of DHS sites and CAGE tag clusters correctly identified active promoters, which are known to contain the three active histone modifications H3K4me2, H3K4me3 and H3K9ac (Bernstein et al, 2005; Kim et al, 2005; Heintzman et al, 2007; Wang et al, 2008) . A similar picture was observed for active promoters in mature B cells (Supplementary Figure S3A) except that we could not detect significant H3K9 acetylation at 22% of these promoters due to a generally low level of H3K9ac, which may reflect the quiescent state of mature B cells ( Figure 2E ; Supplementary Figure S3B and C). In contrast, silent promoters, which were defined as RefSeq-annotated promoters lacking active TSSs (CAGE tags o2.6 RPM), exhibited a radically different chromatin profile (Figure 2A and E).
The distal elements could be divided into five distinct classes according to the presence of different combinations of histone modifications at their DHS site in Rag2 À / À pro-B cells. Three classes (I-III) contained significant amounts of H3K4 monomethylation (H3K4me1; Figure 2B and C), which has previously been associated with enhancers (Heintzman et al, 2007) . These three classes differed, however, in their abundance of active histone modifications. Class I comprising 20% of all distal elements contained the three active marks H3K4me2, H3K4me3 and H3K9ac, class II (12%) was characterized by the presence of H3K4me2 and H3K9ac, and class III (22%) carried only significant levels of H3K4me2 (Figure 2A and B). A large part (41%) of the distal elements (class IV) contained none of the histone modifications analysed, whereas the presence of the repressive H3K27me3 mark defined the smallest (5%) class (V) of distal elements. Importantly, the five different classes of distal elements could be identified in similar relative proportions also in mature B cells (Figure 2E; Supplementary Figure S3B and C) . Recent studies used the occurrence of active histone modifications combined with the expression level of the nearby gene to predict active enhancers in the genome (Creyghton et al, 2010; Rada-Iglesias et al, 2011) . We therefore analysed the transcriptome of Rag2 À / À pro-B cells by RNA sequencing (Mortazavi et al, 2008) to determine the expression level of the genes associated with distinct classes of distal elements. The average transcript level of genes containing elements of Table S1 ). Supplementary Tables S4 and S5 contain the genomic coordinates of the different DE identified in pro-B and mature B cells, respectively. class I and II was high, indicating that these distal elements qualify as active enhancers ( Figure 2D ). In contrast, the average expression of genes comprising class V elements was low, suggesting that these elements are inactive in pro-B cells ( Figure 2D ). Whereas the genes characterized by class III and IV DHS sites were expressed at intermediate levels ( Figure 2D ), only elements of class III significantly changed their chromatin signature during development to mature B cells, thus identifying them as poised distal elements (Supplementary Figure   S3D) . Interestingly, half of the class IV elements (corresponding to 20% of all distal elements) contained both CTCF-and cohesin-binding sites (Supplementary Figure S3E) and thus likely function in gene insulation, chromatin looping or chromosome cohesion (Peters et al, 2008; Phillips and Corces, 2009 ). In conclusion, our genome-wide analyses of DHS sites, TSSs, histone modifications and gene transcripts identified active and inactive promoters, active enhancers (l, II), poised (III) and inactive (V) distal elements as well as DHS sites (IV) enriched in CTCF/cohesin-binding sites in the absence of histone modifications, which together constitute the cisregulatory landscape of committed pro-B and mature B cells.
Pax5 binds to a large part of the cis-regulatory elements in B cells
To map the genomic pattern of Pax5 binding, we took advantage of Pax5
Bio/Bio mice, which exhibit normal B-cell development, although they carry a C-terminal biotin acceptor sequence together with an IRES-BirA gene insertion in the 3' untranslated region of Pax5 . These mice simultaneously express the biotin-tagged Pax5 protein and its modifying biotin ligase BirA (from Escherichia coli), which results in efficient biotinylation of Pax5 in all B lymphocytes . We thus used shortterm cultured pro-B cells from Pax5
Bio/Bio Rag2 À / À mice and ex vivo sorted mature B cells from lymph nodes of Pax5
Bio/Bio mice for streptavidin-mediated chromatin precipitation coupled with deep sequencing (referred to as Bio-ChIP-seq).
As shown in Figure 3A , Bio-ChIP sequencing identified Pax5 peaks with strong enrichment over a low background at the Blnk locus in pro-B and mature B cells. By using a P-value of o10 À 10 for peak calling (Supplementary Figure S4A ), we identified 20 613 and 15 468 Pax5-binding regions with an overlap of 7924 common peaks in pro-B and mature B cells, respectively ( Figure 3B ). By analysing the sequences of common Pax5 peaks with de-novo motif discovery programmes, we identified a complex and degenerate Pax5-binding motif of 15-bp length ( Figure 3C ) that closely resembles the previously described Pax5 consensus recognition sequence (Czerny et al, 1993; Czerny and Busslinger, 1995) . Despite its degeneracy, the Pax5-binding motif could be found on average in 75% of all common and unique Pax5 peaks of pro-B and mature B cells in contrast to its detection in only 5.6% of random DNA sequences ( Figure 3C ). These data therefore confirmed the specificity of Pax5 binding at the peaks identified by Bio-ChIP sequencing. Analysis of Pax5 binding at cis-regulatory elements demonstrated that a majority (72 and 86%) of the Pax5 peaks coincides with DHS sites in pro-B and mature B cells, respectively ( Figure 3D ). Moreover, Pax5 binds to B40% of all DHS sites and thus to a large part of the cis-regulatory landscape in both cell types ( Figure 3E ). Although Pax5 preferentially interacts with active promoters at the two developmental stages, it binds to twice as many active promoters in mature B cells (62%) as compared with pro-B cells (29%). In contrast to distal elements lacking active histone modifications (IV), Pax5 peaks colocalize with a large part of active enhancers (I þ II; 67 and 62%) and poised elements (III; 50 and 35%) in pro-B cells and mature B cells, respectively. Representative examples of Pax5 binding at active enhancers and promoters are shown for selected key transcription factor genes in Supplementary Figure S4B . In summary, these data demonstrate that Pax5 preferentially interacts with active and poised regulatory elements in early and late B lymphocytes.
Expression of a large number of Pax5 target genes in B lymphocytes
The distribution of Pax5 peaks along RefSeq-annotated gene loci is different in the two B-cell types, as the largest number of peaks is localized in the gene body (29%) in pro-B cells and in the promoter region (33%) in mature B cells ( Figure 3F ). Assigning the Pax5 peaks in the promoter and gene body (criterion A) to the respective gene is the least ambiguous way of determining Pax5 target genes, which already resulted in 6680 and 7709 target genes in pro-B and mature B cells, respectively ( Figure 3F ). Relaxing the criterion of peak assignment to a region extending from À 50 kb to þ 50 kb beyond the gene (criterion C) identified a similar number of Pax5 target genes in pro-B cells (7998) and mature B cells (8190), which we used for all further analyses ( Figure 3F ). Given this large number, the identified Pax5 target genes correspond to B38% of all currently annotated genes (21 428) in the RefSeq database (for details see Supplementary Materials and methods).
Transcriptome analyses by RNA sequencing identified similar numbers of lowly (1-10 RPKM) and more highly (410 RPKM) expressed genes in Rag2 À / À pro-B and mature B cells ( Figure 3G ). Notably, Pax5 target genes account for 48 and 61% of all lowly and 53 and 73% of all highly expressed genes in pro-B and mature B cells, respectively ( Figure 3G ). In summary, the genome-wide binding of Pax5 identified B8000 Pax5 target genes, most of which are expressed in pro-B and mature B cells. Figure   S5B and C). The number of regulated genes strongly declined with increasing expression differences between the two pro-Bcell types ( Figure 4C ). However, when we additionally considered Pax5 binding at the regulated genes, we observed a positive correlation between the percentage of Pax5 target genes and the magnitude of differential gene expression ( Figure 4D ; Supplementary Figure S5B and C). This correlation was strongest for activated Pax5 target genes, demonstrating that most activated genes were also directly regulated by Pax5 ( Figure 4D ; Supplementary Figure S5B ). Our analysis thus identified 123 activated and 238 repressed Pax5 target genes, which were more than four-fold regulated by Pax5. Interestingly, 74 and 95% of the activated and repressed Pax5 target genes were novel, as only 32 and 12 of these activated and repressed genes were recently identified as Pax5 target gene by ChIP-chip analysis (McManus et al, 2011) . Importantly, the 361 regulated Pax5 target genes account for 4.5% of all 7998 target Figure S4A) . Average sequence tag density profiles aligned at the centre of the Pax5 peaks are shown for common and unique Pax5-binding sites (right). The genomic coordinates of the Pax5 peaks are provided in Supplementary Table S6. (C) Consensus Pax5 recognition sequence identified by de-novo motif discovery, as described in Supplementary Materials and Methods. The Pax5-binding motif is shown with its information content indicating the size and complexity of the predicted binding. This motif was detected at the indicated frequency (%) in common and unique Pax5 peaks (right), whereas it was found only in 5.6% of random DNA sequences (white line). Table S1 ).
Identification of a relatively small number of regulated Pax5 target genes in pro-B cells
genes, which indicates that only a small subset of the Pax5-bound genes also require Pax5 for their expression in pro-B cells.
Target gene activation by Pax5-mediated induction of active enhancers
We have recently demonstrated that Pax5 is able to induce active chromatin at genomic Pax5-binding sites by recruiting chromatin-remodelling and histone-modifying enzymes . Here, we investigated whether Pax5 may activate its target genes by inducing DHS sites in committed pro-B cells. To this end, we additionally mapped DHS regions in Pax5 Figure S6C ; Nutt et al, 1998) . Together, these data revealed an important function of Pax5 in transcriptional activation and repression by inducing or eliminating active enhancers at B-cell commitment.
Role of Pax5 during the differentiation of CLPs to committed pro-B cells
To investigate the in vivo contribution of the regulated Pax5 target genes to early B-cell development, we next determined how many genes are activated and repressed during the development of ALPs via BLPs to committed pro-B cells (Inlay et al, 2009) . To this end, we isolated ALPs, BLPs and Table S1 ). The RNA-seq data of the regulated Pax5 target genes are shown in Supplementary Table S7 
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Supplementary Figure S7C) . Analysis of the instructive transcription factors E2A, EBF1 and Pax5 revealed that the Tcf3 (E2A) gene was equally expressed in ALPs and BLPs, whereas both Ebf1 and Pax5 were strongly activated in BLPs ( Figure 5C ) in agreement with published data (Inlay et al, 2009 ). The three genes were further activated B4-fold in pro-B cells ( Figure 5C ), consistent with the notion that all three transcription factors contribute to gene regulation during the BLP to pro-B-cell transition.
We next investigated to what extent Pax5 controls the 225 activated and 498 repressed genes that are regulated more than four-fold during the BLP to pro-B-cell transition ( Figure 5B ; Supplementary Figure S7C ). As shown in Figure 5D , we found a strong correlation between the percentage of regulated Pax5 target genes and the magnitude of differential gene expression observed during the BLP to pro-B-cell transition. Hence, genes with high expression differences in this developmental transition were strongly enriched for regulated Pax5 target genes. Analysis of the normalized expression values (RPKM) for the most highly activated and repressed genes (416-fold) unequivocally demonstrated that these genes are not only strongly regulated during the BLP to pro-B-cell transition, but also depend on Pax5 for their regulation in pro-B cells ( Figure 5E and F). This conclusion was confirmed by analysing the 8-to 16-fold regulated gene class (Supplementary Figure S7D and E) . These analyses furthermore revealed that about half of all Figure S8B) . Scatter plot analysis of the normalized expression values (RPM) of all genes revealed that 112 genes (indicated in blue) were more than four-fold activated, and 274 genes (indicated in red) were similarly repressed in wildtype compared with Pax5-deficient mature B cells ( Figure 6A and B). Notably, fewer genes showed strong Pax5-dependent activation or repression in mature B cells ( Figure 6A and B) compared with pro-B cells ( Figure 4B and C), which likely reflects the reduced viability of Pax5-deficient mature B cells (Horcher et al, 2001) . By additionally considering Pax5 binding, we identified 78 activated and 183 repressed Pax5 target genes in mature B cells ( Figure 6C ). Surprisingly however, we observed a minimal overlap between the Pax5-regulated genes identified in pro-B and mature B cells, as only very few genes were more than four-fold activated or repressed at both developmental stages ( Figure 6D ).
To investigate the reason for the low overlap among the regulated Pax5 target genes, we first analysed the 3569 common Pax5 target genes, which were similarly expressed in pro-B and mature B cells as shown by transcriptome comparison of the two cell types (Supplementary Figure  S9A and B) . As expected, the majority of these target genes were not regulated by Pax5 in either cell type (Supplementary Figure S9C) and largely coded for 'house-keeping' functions as shown by Gene Ontology analysis (Supplementary Figure  S9D and E). The few Pax5-dependent genes among the common target genes (Supplementary Figure S9C) could be further distinguished as to whether they were similarly or differently regulated by Pax5 in pro-B and mature B cells. Surprisingly, we identified only 18 commonly repressed genes, which corresponded to 7.4 and 9.7% of all repressed Pax5 target genes in pro-B and mature B cells, respectively (Supplementary Figure S8G) . Likewise, only 13 Pax5 target genes were activated in both cell types, thus constituting 10.6 and 16.7% of the activated Pax5 target genes in pro-B and mature B cells ( Figure 6E) . A second class of activated Pax5 target genes was regulated only in pro-B cells (30 genes) or mature B cells (23 genes), corresponding to 24.3 and 29.5% of the activated target genes in the respective cell type (Supplementary Figure S8C and D) . The loss of Pax5-dependent activation in one of the two cell types could be caused by the absence of certain Pax5 peaks and their associated DHS sites, as exemplified for Ebf1 and Trp53i11 in mature B cells (Supplementary Figure S8E) and Fam43a and Sh3bp2 in pro-B cells (Supplementary Figure S8F) .
The most striking finding of the transcriptome analysis of pro-B and mature B cells was the observed massive change of gene expression within the B-cell lineage, as 417 genes were more than four-fold activated and 1076 genes were similarly repressed during the development of pro-B cells to mature B cells (Supplementary Figure S9A and B) . The large number of differentially expressed genes in pro-B and mature B cells therefore suggested the possibility that a majority of the activated Pax5 target genes might be significantly expressed only at one of the two developmental stages. Indeed, 31 (40%) of the activated Pax5 target genes in mature B cells showed no or only very low expression in pro-B cells, thus indicating that they could not qualify as activated Pax5 target genes in pro-B cells ( Figure 6F ). Consistent with this finding, most of these genes contained only significant levels of the H3K4me2 mark in pro-B cells, which is indicative of poised chromatin (Supplementary Figure S10A) . Moreover, 62 (50.4%) of the activated Pax5 target genes in pro-B cells were either not at all or only lowly expressed in mature B cells ( Figure 6G ). Active chromatin and DHS sites were absent or strongly reduced at most genes of this category in mature B cells, demonstrating that they are epigenetically silenced in late B lymphopoiesis (Supplementary Figure  S10B) . In summary, we conclude that Pax5 largely regulates different target genes in early and late B-cell development.
The observed differential gene regulation could be explained by the selective binding of important transcription factors to Pax5 target genes in pro-B or mature B cells. To investigate this possibility, we searched for transcription factor-binding motifs, which are specifically enriched at Pax5 peaks in pro-B and mature B cells. The DNA-binding motifs for Foxo1, Lmo2 and EBF1 were moderately enriched Figure  S7A) prior to RNA preparation and RNA sequencing. Normalized expression values (RPM) were calculated for each gene in the three cell types, and the gene expression differences between ALPs and BLPs (A) and between BLPs and Rag2 À / À pro-B cells (B) were analysed as described in Figure 4B . The RNA-seq data of the genes regulated during these developmental transitions are shown in Supplementary Table S8 Pax5 function in pro-B and mature B cells R Revilla-i-Domingo et al data of pro-B and mature B cells (Vilagos et al, 2012) . EBF binding was detected at 2913 (14%) of all Pax5 peaks in pro-B cells (Supplementary Figure S10D and E) . Importantly, the frequency (23.9%) of Pax5 peaks with EBF1 binding significantly increased at activated Pax5 target genes in pro-B cells, which suggests a critical role for EBF1 in the regulation of these genes in early B-cell development (Supplementary Figure  S10E) . In contrast, we identified only 281 EBF1 target genes in mature B cells (Vilagos et al, 2012) , which resulted in the colocalization of only 1.2% of all Pax5 peaks with EBF1-binding sites in mature B cells (Supplementary Figure S10D-F) . Together, these data indicate that EBF1 is involved in the regulation of activated Pax5 target genes in early B lymphopoiesis, whereas other transcription factors, such as Sp1, Myc, Cnot3, Zfx and Maz, likely contribute to the activation of Pax5 target genes in late B-cell development.
Function of regulated Pax5 target genes
The 123 activated Pax5 target genes identified in pro-B cells ( Figure 4D ) code for proteins of distinct functions with three large classes consisting of 26 cell surface and adhesion receptors, 18 intracellular signal transducers and 16 transcriptional regulators ( Figure 7A ). The 78 activated Pax5 target genes in mature B cells ( Figure 6C ) revealed a similar distribution of protein function, coding for 9 cell surface receptors, 13 signal transducers and 9 transcriptional regulators ( Figure 7A ). These three classes contain only four genes (Cd19, Cd79a, Bcar3 and Sbk1; bold in Figure 7 ), which are commonly activated in pro-B and mature B cells, further demonstrating that Pax5 mainly regulates different genes in the two cell types. Several activated target genes in pro-B cells have known functions during B-cell development (blue; Figure 7A ), as they code for structural or regulatory proteins involved in pre-BCR signalling (Cd19, Cd79a, Vpreb1, Vpreb3, Igll1, Blnk, Prkd2), inhibition of signalling (Siglecg, Cd22, Slamf6, Slamf7), B-cell adhesion and migration (Bst1, Epha2, Sdc1, Sdc4, Bcar3, Nedd9) or transcriptional regulation (Ikzf3, Lef1, Bach2, Id3, Tcf7l2, Foxo1, Pou2af1, Spib, Irf4). In mature B cells, we identified fewer activated target genes (blue; Figure 7B ) with known functions in BCR signalling (Cr2 [Cd21], Cd19, Cd79a, Sh3bp2), inhibition of signalling (Cd72), B-cell trafficking and homing (Ccr6, Cd55, Bcar3) and transcriptional regulation (Klf2, Id2). Protein functions were also assigned to the 238 and 183 repressed Pax5 target genes identified in pro-B cells ( Figure 4D ) and mature B cells ( Figure 6C ), respectively (Supplementary Figure S11) . Cell surface receptors, signal transducers and transcriptional regulators are encoded by 39, 45 and 26 repressed target genes in pro-B cells and 23, 35 and 24 repressed target genes in mature B cells, respectively (Supplementary Figure S11) . Hence, Pax5 down-regulates the expression of multiple receptors, signalling molecules and transcription factors, many of which play important roles in other hematopoietic cell types. Only seven genes of these three classes are commonly repressed in pro-B and mature B cells. One of these genes is Pax5, suggesting that Pax5 is involved in fine-tuning of its own expression ( Supplementary Figures S8G and S11 ).
Discussion
The transcription factor Pax5 controls the development, identity and function of B cells by repressing B-lineageinappropriate genes and activating B-cell-specific genes . Here, we have investigated the direct transcriptional effects of Pax5 by genome-wide analyses, demonstrating that Pax5 binds to a large part of the cis-regulatory genome corresponding to B8000 Pax5 target genes in pro-B and mature B cells. However, only a small subset of these target genes also depend on Pax5 for their expression in pro-B cells (4.5%) and mature B cells (3.2%). Nevertheless, the regulated Pax5 target genes in pro-B cells account for a large part of the gene expression changes that occur during the developmental transition from BLPs to committed pro-B cells. Notably, we observed only a minimal overlap between regulated Pax5 target genes in pro-B and mature B cells, indicating that Pax5 controls the identity and function of B lymphocytes by regulating a relatively large but different spectrum of target genes in early and late B-cell development.
Genome-wide profiling of histone modifications has successfully been used for defining cis-regulatory elements and predicting gene activity in different cell types (Heintzman et al, 2007; Wang et al, 2008; Creyghton et al, 2010; Lin et al, 2010; Ernst et al, 2011; Northrup and Zhao, 2011; RadaIglesias et al, 2011) . Here, we have employed a novel approach for analysing the cis-regulatory landscape by genome-wide mapping of all protein-DNA interaction sites (DHS sites) and active TSSs (CAGE) to define distal elements and active promoters in pro-B and mature B cells. The profiling of histone modifications was subsequently used to categorize the distal elements according to their chromatin signature as active enhancers or poised and inactive elements. The overall organization of the cis-regulatory landscape is comparable in pro-B and mature B cells containing 36 844 and 31087 DHS sites, respectively. Among these DHS Figures  S3A and S8A) . The RNA-seq data of the two cell types are shown by scatter plot analysis (A) and gene expression (significance) differences (B) as described in Figure 4B sites, active promoters (28 and 31%), active enhancers (23 and 21%), poised elements (16 and 13%) and inactive distal elements (3 and 5%) are present in similar proportions in pro-B and mature B cells, respectively. Surprisingly, 30% of all DHS sites (distal element class IV) in both cell types do not contain any significant amount of the active or repressive histone modifications analysed, but are enriched in CTCFand cohesin-binding sites, indicating that they may be involved in gene insulation, chromatin looping or chromosome cohesion (Peters et al, 2008; Phillips and Corces, 2009) .
Pax5 interacts with a large part (40%) of the cis-regulatory landscape in both B-cell types, as it binds to 20 613 and 15 468 genomic sites defining B8000 target genes in pro-B and mature B cells, respectively. Pax5 is not unique in this 
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Pax5 function in pro-B and mature B cells R Revilla-i-Domingo et al respect, as even higher numbers of binding sites have been reported for the transcription factor PU.1 in B cells (B33 000; Heinz et al, 2010) , CTCF in pro-B cells (B49 000; Ebert et al, 2011) and MyoD in myoblasts (B60 000; Cao et al, 2010) . In contrast, fewer binding sites and thus less target genes were identified for EBF1 and E2A in pro-B cells Treiber et al, 2010; Vilagos et al, 2012) , GATA3 in T cells (Wei et al, 2011) and GATA1 in erythroblasts (Soler et al, 2010) . The high number of genomic Pax5-binding sites could reflect the flexible sequence recognition by the DNA-binding paired domain of Pax5. While we previously identified a degenerate Pax5-binding sequence of 15-bp length (Czerny et al, 1993; Czerny and Busslinger, 1995) , ChIP sequencing has now refined this degenerate recognition motif. The paired domain of Pax5 is known to recognize DNA through three different binding modules, as the N-and C-terminal helixturn-helix domains recognize distinct DNA-binding motifs in adjacent major grooves of the DNA helix, whereas the linker between the two domains contacts the minor groove (Xu et al, 1995; Garvie et al, 2001) . The crystal structure of the paired domain-DNA complex (Garvie et al, 2001) indicates that the residues 1-3 and 13-15 of the Pax5 recognition sequence ( Figure 3C ) mediate the major groove contacts and residues 5-10 the minor groove contacts of the paired domain. The degeneracy of sequence recognition is best explained by the observation that none of the three DNAbinding modules recognize their motif with highest affinity, which allows for considerable variability of the recognition sequence (Czerny et al, 1993) . Although Pax5 preferentially binds to active promoters, active enhancers and poised distal elements, it is not required for the expression of most (495%) of its target genes. A similar discrepancy between transcription factor binding and gene regulation has recently been observed for EBF1 and GATA3 in pro-B and T cells, respectively (Treiber et al, 2010; Wei et al, 2011) . This disparity could be explained in different ways. Transcription factors recognizing a simple or degenerate sequence motif like Pax5 may fortuitously interact with binding sites in accessible chromatin at active enhancers and promoters, although other transcription factors open up and control these regulatory elements in pro-B or mature B cells. Alternatively, Pax5 may be essential for the regulation of some of its target genes at another developmental stage or under specific stimulation conditions that we did not investigate. It has been suggested that lineage-determining factors such as PU.1, MyoD and Pax5 bind to a large part of the cis-regulatory landscape to maintain cell identity through global organization of the genome in the one-and threedimensional space (Natoli, 2010) . However, functional evidence for this hypothesis is currently missing particularly
Signal transducer Figure 4D ) or wildtype and Pax5-deficient mature B cells ( Figure 6C ). Genes with a significance value of 483 (416-fold) or between 83 and 47 (16-to 8-fold) are indicated by red and green boxes, respectively, whereas the remaining genes are characterized by a significance value ranging from 47 to 20 (eight-to four-fold). Genes that are commonly activated in both cell types are indicated in bold, and genes with a known function in B lymphopoiesis are shown in blue. Signalling adaptors (A), kinases (K) and phosphatases (P) are indicated.
in view of the fact that Pax5 is dispensable for the expression of most of its target genes.
A remarkable aspect of our analysis is the identification of only a small number of activated (1.54 and 1.0%) and repressed (3.0 and 2.2%) Pax5 target genes in pro-B and mature B cells, respectively. Our genome-wide data also demonstrate that Pax5 represses twice as many genes as it activates in the two B-cell types. Importantly, we analysed the spectrum of regulated Pax5 target genes in pro-B cells in the context of the gene expression changes that are responsible for B-cell specification and commitment during the transition of ALPs to committed pro-B cells. This process is controlled by the transcription factors E2A, EBF1 and Pax5, whereby E2A activates Ebf1 possibly through Foxo1 induction (Welinder et al, 2011 ) and EBF1 in turn activates the Pax5 gene to accomplish B-cell commitment (Nutt and Kee, 2007; Decker et al, 2009) . Surprisingly, the pattern of Ebf1 and Pax5 expression is quite similar in ALPs, BLPs and pro-B cells (this study ; Inlay et al, 2009) , suggesting that EBF1 rapidly induces Pax5 expression consistent with the fact that the intronic Pax5 enhancer is already activated in multipotent hematopoietic progenitors (Decker et al, 2009) . Interestingly, Pax5 regulates a large part of the genes that are repressed (22%) or activated (27%) during the developmental transition from BLPs to committed pro-B cells. Hence, these genome-wide molecular data further document the importance of Pax5 for B-cell commitment.
Recently, Pax5 was shown to rapidly induce active chromatin marks at activated target genes and to remove active histone modifications at repressed target genes by recruiting chromatin-remodelling and histone-modifying protein complexes . At the global scale, we now demonstrate that Pax5 binding correlates with the induction of active enhancers and promoters at activated Pax5 target genes, whereas the loss of DHS sites is associated with repression of Pax5 target genes in committed pro-B cells. Together, these data indicate that Pax5 functions as an epigenetic regulator to control target gene expression by activating enhancers at activated target genes and by eliminating DHS sites at repressed target genes.
An unexpected finding of our study was the discovery that Pax5 predominantly regulates different genes in early and late B-cell development, as only 13 target genes are commonly activated and 18 target genes are commonly repressed in pro-B and mature B cells. However, Pax5 interacts with a similarly high number of genomic binding sites defining 8000 target genes in both cell types consistent with the fact that Pax5 is similarly expressed in pro-B and mature B cells (Fuxa and Busslinger, 2007) . Surprisingly, the development of pro-B cells to mature B lymphocytes is accompanied by a twofold larger change of gene expression within the B-cell lineage (417 up-and 1076 down-regulated genes) as compared with the developmental transition of BLPs to pro-B cell during B-cell commitment (225 up-and 498 down-regulated genes). This massive change of gene expression largely explains the different spectrum of activated Pax5 target genes in pro-B and mature B cells, as half of all activated target genes in one B-cell type do not qualify as regulated target genes in the other cell type, where they are not at all or only very lowly expressed. As a consequence, Pax5 regulates genes with different functions in pro-B and mature B cells.
The observed differential gene regulation by Pax5 in early and late B lymphopoiesis can be explained by epigenetic and transcriptional mechanisms. First, target genes, which are activated by Pax5 only in mature B cells, predominantly contain poised chromatin in pro-B cells, indicating that their chromatin structure does not support expression in early B-cell development. Moreover, target genes, which are activated by Pax5 exclusively in pro-B cells, are epigenetically silenced by the loss of active chromatin and DHS sites in mature B cells. Second, motif enrichment analyses identified a few transcription factors that may selectively bind to Pax5 target genes in pro-B or mature B cells. The binding of one of these transcription factors, EBF1, was shown by ChIP sequencing to be strongly enriched at the Pax5 peaks of a significant fraction of activated target genes in pro-B cells, which suggests a critical role for EBF1 in the regulation of these genes in early B-cell development.
Expression microarray analyses of pro-B cells previously demonstrated that Pax5 represses B-lineage-inappropriate genes involved in receptor signalling, cell adhesion, migration, transcriptional control and cellular metabolism in other hematopoietic lineages (Delogu et al, 2006) , while simultaneously activating genes encoding regulatory and structural proteins important for B-cell signalling, trafficking, differentiation and immune function (Schebesta et al, 2007) . By extending these expression analyses to the genome-wide scale and by defining the spectrum of regulated target genes in pro-B and mature B cells, we now demonstrate that Pax5 directly activates and represses different genes encoding signalling and adhesion receptors, intracellular signal transducers and transcriptional regulators in early and late B-cell development. We therefore conclude that Pax5 controls B-cell identity not by regulating the same target genes throughout B lymphopoiesis, but rather by controlling a relatively large but different set of genes involved in receptor signalling and transcriptional regulation in pro-B and mature B cells.
In summary, we have deciphered the role of Pax5 in gene transcription at the genome-wide level during normal B lymphopoiesis. Importantly, Pax5 is also implicated as a haploinsufficient tumour suppressor or oncogenic translocation fusion protein in the generation of human B-cell precursor acute lymphoblastic leukaemia (B-ALL; Mullighan et al, 2007; Nebral et al, 2009) . Hence, our genome-wide characterization of Pax5 target genes has set the stage for future investigations to identify the spectrum of Pax5 target genes that contribute to B-ALL development upon deregulation by distinct PAX5 mutations.
Materials and methods
Mice
All mouse strains were maintained on the C57BL/6 background. Animal experiments were carried out according to valid project licences, which were approved and regularly controlled by the Austrian Veterinary Authorities.
Flow cytometry
Bone marrow and lymph node cells were stained for flow cytometry with the following antibodies: anti-B220/CD45R (RA3-6B2), CD3e (145-2C11), CD4 (GK1.5), CD5 (53-7.3), CD8a (2.43), CD11b/Mac1 (M1/70), CD11c (HL3), CD19 (1D3), CD21 (7G6), CD23 (B3B4), CD25/IL-2Ra (PC61), CD43 (S7), CD49b (DX5), CD117/c-Kit (ACK4), CD127/IL-7Ra (A7R34), CD135/Flt3 (A2F10.1), Gr1 (RB6-8C5), IgD (1.19), IgM a (Igh-6a/DS-1), IgM b (AF6-78), Ly6C (6C3), Ly6D (49H4.3), NK1.1 (PK136), Sca1/Ly6A (D7), TCRb (H57-597) and Ter119 (TER119) antibodies.
